Receptor tyrosine kinase inhibitor Sunitinib and integrin antagonist peptide HM-3 show similar lipid raft dependent biphasic regulation of tumor angiogenesis and metastasis
Type
Retraction
Notice date
2/17/2020 0:00
Journal
Journal of Experimental & Clinical Cancer Research: (CR)